Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1290235 | 0.87 | MAPT (0.46) | MAPTMEN1ALDH1A1KMT2ANR1H2 | |
| SCHEMBL19643234 | 0.85 | EPHX1 (0.46) | MAPTMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL19420075 | 0.85 | EPHX1 (0.46) | MAPTMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL24209530 | 0.84 | MEN1 (0.50) | MAPTMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL28391236 | 0.84 | MEN1 (0.40) | MAPTMEN1ALDH1A1KMT2ANR1H2 | |
| SCHEMBL23762130 | 0.82 | MAPT (0.51) | MAPTMEN1ALDH1A1KMT2AUSP2 | |
| SCHEMBL17081077 | 0.79 | NR1H2 (0.44) | MAPTMEN1ALDH1A1KMT2ANR1H2 | |
| SCHEMBL950867 | 0.79 | NR1H2 (0.44) | MAPTMEN1ALDH1A1KMT2ANR1H2 | |
| SCHEMBL21597812 | 0.79 | NR1H2 (0.44) | MAPTMEN1ALDH1A1KMT2ANR1H2 | |
| SCHEMBL29070006 | 0.78 | USP2 (0.44) | MAPTNR1H2USP2SMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116162375-A | Camouflage liquid crystal composite coating with randomly changed image | 西京学院 | 2023-05-26 | — | — | CN | claimed |
| CN-113773240-B | Preparation method of gemifloxacin side chain compound | 北京阳光诺和药物研究股份有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-113773240-A | Preparation method of gemifloxacin side chain compound | 北京阳光诺和药物研究股份有限公司 | 2021-12-10 | — | — | CN | claimed |
| CN-109096415-B | Olefin polymerization catalyst component, process for producing the same, olefin polymerization catalyst, and process for producing olefin polymer | 中国石油化工股份有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-109096416-B | Olefin polymerization catalyst component, process for producing the same, olefin polymerization catalyst, and process for producing olefin polymer | 中国石油化工股份有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-104072498-A | Synthetic method for (R)-N-[5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-3-yl]-4-(4-methyl piperazine-1-yl)benzamide | UNIV SHENYANG PHARMACEUTICAL | 2014-10-01 | — | — | CN | claimed |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| WO-2025134078-A1 | ORGANIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMS) | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-06-26 | — | — | WO | disclosed |
| CN-119431365-A | Phenyl heterocyclic derivative-containing regulator and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4367123-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | Glenmark Specialty S.A. (CH) | 2024-05-15 | — | — | EP | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117730083-A | Pyrimidine compounds as MAP4K1 inhibitors | 格兰马克专业公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-1999044991-A1 | PROCESS FOR PREPARING A PROTECTED 4-AMINOMETHYL-PYRROLIDIN-3-ONE | LG CHEMICAL LTD. (KR) | 1999-09-10 | — | — | WO | disclosed |
| EP-0688772-B1 | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituents and processes for their preparation | LG CHEMICAL LTD (KR) | 1999-05-06 | — | — | EP | disclosed |
| US-5869670-A | BACTERICIDES | LG CHEMICAL LTD. (KR) | 1999-02-09 | — | — | US | disclosed |
| US-5776944-A | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof | LG CHEMICAL LTD. (KR) | 1998-07-07 | — | — | US | disclosed |
| US-5698570-A | QUINOLONE ANTIBIOTIC; BACTERICIDES | LG CHEMICAL LTD. (KR) | 1997-12-16 | — | — | US | disclosed |
| US-5633262-A | BACTERICIDES | LG CHEMICAL LTD. (KR) | 1997-05-27 | — | — | US | disclosed |
| EP-0688772-A1 | Novel quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituents and processes for their preparation | LG Chemical Limited (KR) | 1995-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | MAPT 663/4885MEN1 3993/4885ALDH1A1 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.